ClinicalTrials.Veeva

Menu

The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation

Yonsei University logo

Yonsei University

Status

Unknown

Conditions

End-stage Renal Disease

Study type

Observational

Funder types

Other

Identifiers

NCT04575077
4-2020-0748

Details and patient eligibility

About

High hepcidin concentrations indicate that iron is blocked from secretion from the reservoir. Hepcidin may be useful in prediction functional iron utilization in renal failure patients. Hepcidin is also associated with chronic renal failure and residual renal function in dialysis patients. Recent studies have shown that hepcidin is a potential marker of impaired renal function in a rat model of chronic nephropathy.

The purpose of this study was to investigate the relationship between preoperative hepcidin levels and the incidence of success rate of kidney transplantation in patients with end-stage renal failure undergoing kidney transplantation surgery. The study is a prospective single-group observational study that analyzes hepcidin as a biomarker.

Full description

POD-1 : Researchers will meet patients scheduled for surgery and explain the study. (enroll) the operation date : The patient will sign the consent form. Researchers will collect the blood sample from the patient for testing hepcidin during the operation and record laboratory data performed before surgery POD 1: laboratory test discharge date : laboratory test 6 months after surgery ; Researchers will determine the graft failure of the patient.

* laboratory test ; reticulocyte count, Hb, plasma hepcidin, iron profiles (serum iron, serum ferritin, total iron-binding capacity, transferrin, transferrin saturation), coagulation profiles (PT, PTT), routine urinary analysis, and chemical profiles (aspartate aminotransferase (AST)/alanine aminotransaminase (ALT), serum creatinine, electrolytes, C-reactive protein (CRP), estimated glomerular filtration rate (GFR)), ESR, cystatin C, NGAL, pro BNP, troponin T and urinary analysis

Enrollment

200 estimated patients

Sex

All

Ages

19 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. The patients who plan to undergo kidney transplantation
  2. ASA III-IV
  3. adult over 19 years old

Exclusion criteria

  1. emergent case
  2. heart disease
  3. arrhythmia
  4. BMI >30kg/m2
  5. allergy to some drugs
  6. if other co-operation is planned
  7. foreigner
  8. Illiteracy

Trial contacts and locations

1

Loading...

Central trial contact

Bon-Nyeo Koo, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems